Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Bob Trocchi who wrote (17593)	3/2/1999 8:08:00 PM
From: BDR	Respond to of 18691

<<What do you think about MCHM?>> I haven't looked at MCHM in a while but the method of treatment is worse than MUSE with even less likelihood that the drug will get to where it is needed and greater likelihood that it will go where it is not (side effects). I foresee a very small niche for this product assuming they can prove any effectiveness at all. Will look at it for a short.

To: Bob Trocchi who wrote (17593)	3/2/1999 9:42:00 PM
From: Mark L.	Read Replies (2) \| Respond to of 18691

This is a note I sent to Bill Wexler earlier today, mentioning MCHM: Twenty employees, $240 million market cap, no Schering-Plough (or anyone else) to market their ED drug, a long history of management not delivering on projections, a too easily-grasped concept, and rabid, misinformed evangelists on their Yahoo! board. It's had a nice run-up the last couple of days on mini-orders (only a couple of blocks). The Topiglan drug has an additional problem that I've not seen mentioned elsewhere. Let's just suppose hypothetically--for the sake of argument--that Topiglan works. Now you've got an erection. You've still only solved half the problem. Now you've got to find a woman who will let you insert your erect penis, covered with a drug that is designed to seep through the skin, and thereby deposit a hefty amount of the drug into her system. I believe that such women are rare.